감작된 환자에서 rituximab 유도 요법을 이용한 3차 신장 이식 1례 = A Case of Successful Third Renal Transplantation Using Rituximab(anti-CD20 Monoclonal Antibody) in a Highly Sensitized Patient

다국어 초록 (Multilingual Abstract)

Rituximab, chimeric murine/human anti-CD20 monoclonal antibody, has been currently used as treatment of follicular non-Hodgkins lymphoma and posttransplantation lymphoproliferative disease. Nowadays, rituximab has also been utilized in the renal transplantation to get over acute rejection in highly sensitized patients. We hereby report a case of successful renal transplantation in a highly sensitized patient, who has been done the 3rd renal transplantation. A 44-year-old male patient admitted for the 3rd renal transplantation. His previous 2 transplantations failed because of acute rejection. We tried plasmapheresis and intravenous immunoglobulin, widely used as pretransplantation management in high risk patients. In addition to these, we applied 2 times of rituximab (375 mg/m2) before transplantation at interval of 1 week. The renal function of the patient has been within the normal range without any evidence of rejection 6 months after transplantation.

참고문헌 (Reference)

1 Becker YT, "The emerging role of rituximab in organ transplantation" 19 : 621-628, 2006

2 박의순, "Rituximab으로 치료한 신이식 환자에서 발생한 이식 후 림프구 증식성 질환 1예" 대한내과학회 67 (67): 94-99, 2004

3 Lee SU, "Rituximab rescue for refractory antibody mediated rejection after kidney transplantation" 18 : 140-143, 2004

4 Ruggenenti P, "Rituximab in idiopathic membranous nephropathy : a one-year prospective study" 14 : 1851-1857, 2003

5 Vieira CA, "Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics" 77 : 542-548, 2004

6 Becker YT, "Rituximab as treatment for refractory kidney transplant rejection" 4 : 996-1001, 2004

7 Sfikakis PP, "Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial" 52 : 501-513, 2005

8 Gloor JM, "Overcoming a positive crossmatch in living-donor kidney transplantation" 3 : 1017-1023, 2003

9 Book BK, "New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies" 37 : 640-642, 2005

10 Sarwal M, "Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling" 349 : 125-138, 2003

11 Salama AD, "Drug insight: rituximab in renal disease and transplantation" 2 : 221-230, 2006

12 Benz K, "Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy" 19 : 794-797, 2004

13 Donauer J, "ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab : a single center experience" 13 : 108-110, 2006

14 Tyden G, "ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab" 5 : 145-148, 2005

15 Saleh MN, "A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia" 27 (27): 99-103, 2000